Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors at 7 institutions in 4 countries.
Ángela Del Castillo-IzquierdoDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0002-0140-1418
José María Moreno-NavarreteDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0002-2883-511X
Jessica LatorreDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0002-7603-1458
María Arnoriaga-RodríguezDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.
Marta BallantiDepartment of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Giovanni MonteleoneCenter for Atherosclerosis, Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1339-9076
Omero Alessandro PaoluziCenter for Atherosclerosis, Policlinico Tor Vergata, 00133 Rome, Italy.
Geltrude MingroneDepartment of Internal Medicine, Catholic University, 00168 Rome, Italy.
Josep PuigDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0003-2791-6599
Rafael RamosDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.
Josep Garre-OlmoNutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain.
Mariona JovéDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), 25198 Lleida, Spain.ORCID 0000-0001-5577-6162
Reinald PamplonaDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), 25198 Lleida, Spain.
Manuel Portero-OtínDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), 25198 Lleida, Spain.ORCID 0000-0002-1823-0299
Joaquim SolDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), 25198 Lleida, Spain.ORCID 0000-0003-1424-8958
Philippe LefebvreInstitut Pasteur de Lille, Université Lille, Inserm, CHU Lille, F-59000 Lille, France.ORCID 0000-0002-9366-5129
Massimo FedericiDepartment of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
José Manuel Fernández-RealDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0002-7442-9323
Jordi Mayneris-PerxachsDepartment of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.ORCID 0000-0003-3788-3815
Universitat de Girona · ESUniversitat de Lleida · ESInstituto de Salud Carlos III · ESInserm · FRPoliclinico Tor Vergata · ITUniversity of Rome Tor Vergata · ITUniversità Cattolica del Sacro Cuore · IT
Funding
Fundació Marató de TV3 201612-31Instituto de Salud Carlos III CM19/00190Instituto de Salud Carlos III CP18/00009Instituto de Salud Carlos III PI20/01090Marie Skłodowska-Curie Innovative Training Network 859890
6 · The paper itself
Abstract
Dipeptidyl peptidase 9 (DPP9) is a member of the dipeptidyl peptidase IV family. Inhibition of DPP9 has recently been shown to activate the nucleotide-binding domain leucine-rich repeat 1 (NLRP1) inflammasome. NLRP1 is known to bind nucleic acids with high affinity and directly interact with double stranded RNA, which plays a key role in viral replication.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
DPP9 as a Potential Novel Mediator in Gastrointestinal Virus Infection. · full record | OpenQuestion